Editas Q4 2020 Earnings Report
Key Takeaways
Editas Medicine reported a net loss of $62.5 million for the fourth quarter of 2020. The company dosed the first patient in the adult mid-dose cohort of the BRILLIANCE trial of EDIT-101 for LCA10 and initiated the Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease. They ended the year with a strong cash position of $512 million.
Dosed first patient in adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10.
Initiated Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease.
Appointed James (Jim) C. Mullen as President and Chief Executive Officer.
Ended 2020 with strong cash position of $512 million.
Editas
Editas
Forward Guidance
Editas medicine expects that its existing cash, cash equivalents and marketable securities of $512 million at December 31, 2020, will enable it to fund its operating expenses and capital expenditures into 2023.